Search
for
Sort by
Research 181–210 of 1000+
- Atypical Case of Minoxidil-Induced Generalized Anasarca and Pleuropericardial Effusion
- Shedding light on therapeutics in alopecia and their relevance to COVID-19
- Transgender and Migraine
- An overview of management of drug-induced hair and nail disorders
- COVID‐19, androgens, and androgenic alopecia
- Medication Repurposing: New Uses for Old Drugs
- Androgens in SARS-CoV-2 Coronavirus Infections
- Proxalutamide Reduction of Mortality Rate in Hospitalized COVID-19 Patients Depends on Treatment Duration – an Exploratory Analysis of the Proxa-Rescue AndroCoV Trial
- Severe hair loss associated with psyc hotropic drugs in psychiatric inpatients—Data from an observational pharmacovigilance program in German-speaking countries
- The spectrum of nephrocutaneous diseases and associations
- Significance of iron status in hair loss in women
- Autoimmune thyroid disease and human health: a systematic review of Mendelian randomization studies
- TMPRSS2: A Key Host Factor in SARS-CoV-2 Infection and Potential Therapeutic Target
- A Cell Membrane-Level Approach to Cicatricial Alopecia Management: Is Caveolin-1 a Viable Therapeutic Target in Frontal Fibrosing Alopecia?
- Acne
- Cutaneous Drug Eruptions Associated with the Use of Biologies and Cutaneous Drug Eruptions Mimicking Specific Skin Diseases
- Diseases of the Hair and Nails
- Estimation of renin and D-dimer levels in women with polycystic ovary disease with or without coronavirus infection
- Interpretation of Laboratory Data and General Physical Examination by Pharmacists
- Cutaneous Reactions to Drugs
- Primary cicatricial alopecia and inflammatory bowel disease – is there a link?
- Telogen Effluvium
- Menopause
- Topical Spironolactone in the Treatment of Ocular Graft-Versus-Host Disease
- Skin
- A Child with Nonscarring Alopecia
- LUPUS ERYTHEMATOSUS AND THE SKIN
- Regulation of the human hair cycle
- Benefit-Risk Assessment of GLP-1 Receptor Agonists: Implications for Dermatologists and Plastic Surgeons
- Evaluation of COVID-19 risk in patients on systemic retinoid therapy